Larry Anderson, Jr. , John Berk, Anita D'Souza, David Hughes, Sami Khella, Mathew Maurer, Lisa Mendelson, Vaishali Sanchorawala

Larry Anderson, Jr. , MD, PhD

Associate Professor, Division of Hematology / Oncology, UT Southwestern Medical Center

Dr. Anderson is the director of the Myeloma, Waldenstrom’s, and Amyloidosis Program at UT Southwestern Medical Center in Dallas. He focusses solely on treatment of plasma cell disorders including multiple myeloma, Waldenstrom’s macroglobulinemia, amyloidosis, and other gammopathies. He specializes in treating these diseases with stem cell transplantation but also takes care of these patients from diagnosis through long term follow up. He has over 13 years of experience with stem cell transplantation after completion of his medical oncology fellowship at Fred Hutchinson Cancer Research Center in Seattle. He did his residency in internal medicine at Mayo Clinic Rochester and his MD and PhD degrees were received from UT Houston Medical School and MD Anderson Cancer Center in Houston. He runs an active clinical trial program for the spectrum of plasma cell disorders with a focus on immunotherapies and CAR T-cell therapy. He and his team (including Dr. Ankit Kansagra) have established the first multidisciplinary amyloidosis program in the region (UTSW MAP).

Back to top

John Berk, MD

Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine, Boston University School of Medicine

Dr. Berk is assistant director of the Amyloidosis Center at Boston University Medical Center. He led the Diflunisal Trial, and has focused on drug development for ATTR amyloidosis for than 15 years. He and his research team have participated in all of the major clinical trials for patients with ATTR amyloid polyneuropathy and cardiomyopathy.

Back to top

Anita D'Souza, MD, MS

Associate Professor, Hematology and Medical Oncology, Froedtert & Medical College of Wisconsin

Dr. Anita D’Souza, MD, MS is an Associate Professor of Medicine at the Medical College of Wisconsin in Milwaukee. She is a hematologist/oncologist and treats patients with plasma cell disorders including light chain amyloidosis and multiple myeloma. She is an outcomes researcher conducting patient-centered clinical research in these diseases.

Back to top

David Hughes, PharmD, BCOP

It should read Clinical Pharmacy Specialist, Hematology/Oncology, Boston Medical Center

Dr. Hughes is a clinical pharmacy specialist Boston Medical Center/Boston University School of Medicine (BUSM). His practice revolves around the management of hematology/oncology patients and has a special interest in supportive care and transitions of care. He also has a large role in support of patients within the BUSM Amyloidosis Center. He works closely with the providers within the Amyloidosis Center to help patients access their new amyloidosis therapies. He and his team allow for optimal care of patients by helping alleviate operational boundaries and clinical support and monitoring as it relates to these new therapies

Back to top

Sami Khella, MD

Chief, Department of Neurology, Penn Presbyterian Medical Center

Dr. Khella has more than 20 years experience in diagnosing and treating patients with a variety of neurologic diseases. As a neuromuscular specialist, he performs electromyography and interprets evoked potentials. Over 20 years ago, he co-founded the Penn Amyloid Center, which has grown into one of the biggest Amyloid programs in the US. Dr. Khella has been involved in pivotal hereditary ATTR amyloidosis clinical trials and is the author or co-author of many papers detailing this disease as well as other neuromuscular diseases.

Back to top

Mathew Maurer, MD

Professor of Medicine, Columbia University Irving Medical Center

Mathew S. Maurer, MD, is the Arnold and Arlene Goldstein Professor of Cardiology and Director of the Cardiac Amyloidosis Program at NewYork-Presbyterian Hospital / Columbia University Irving Medical Center. A general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation, he has received grants from the National Institute on Aging and National Heart Lung Blood Institute to study cardiovascular changes in older adult patients and specializes in the care of patients with heart failure and a preserved ejection fraction, including patients with amyloidosis and HCM. He has been involved in numerous pivotal amyloidosis clinical trials and has conducted extensive research for both the treatment as well as early detection of ATTR amyloidosis.

Back to top

Lisa Mendelson, BSN, MSN, ANP-BC

Assistant Professor of Medicine, Boston University School of Medicine

Ms. Mendelson is a board certified nurse practitioner who obtained her nursing education from MGH Institute of Health Professions in Boston, MA in 2010. She then went on to work in cardiology and hepatology before joining the Boston University Amyloidosis Center in 2017. Since joining the Amyloidosis Center Ms. Mendelson has co-authored multiple publications with a focus on increasing disease awareness among the nursing community. She was inducted into the Boston University Medical Group Clinical Excellence Society in 2019 for her work at the center.

Back to top

Vaishali Sanchorawala, MD

Director, Amyloidosis Center, Boston University School of Medicine

Dr. Sanchorawala is the director of the Amyloidosis Center at Boston University School of Medicine, one of the country’s leading centers for the research and treatment of systemic and localized amyloidosis. She has been involved in the center since 1994 and was appointed director in January 2017. She is a leader in the field of amyloidosis research and is currently running several clinical trials mostly focused on treatment of AL amyloidosis. Dr. Sanchorawala extends her efforts outside of the clinic by participating in research organizations and discussions with the FDA, truly dedicating her career to the advancement of amyloidosis treatment and the well-being of her patients.

Back to top